智通财经APP获悉，东阳光药(06887)尾盘涨超4%，截至发稿，涨4.38%，报47.7港元，成交额1498.24万港元。
消息面上，10月11日，中国国家药品监督管理局官网公示，广东东阳光药业按化药注册分类申报的盐酸芬戈莫德胶囊获批上市，拿下国内首仿，也是该公司首款口服免疫抑制剂。据悉，芬戈莫德是全球首个治疗多发性硬化症(MS)的口服药物，由诺华和日本三菱制药共同开发，2010年在美国获批上市，2016-2020年全球销售额均保持在30亿美元以上。
招商证券发布研报称，东阳光药作为中国吸收合并及介绍上市第一股，通过吸收合并的方式构筑研产销一体化平台创新药企。研发方向聚焦抗感染、慢病(代谢)、肿瘤三大领域，研发管线储备丰富，已上市产品快速放量，开启全球创新崭新篇章。该行看好公司创新管线发展，首次覆盖，给予“强烈推荐”投资评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.